There are currently 501 clinical trials in Tucson, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Arizona, Banner University Medical Center - Tucson, Arizona Cancer Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
NCT06016088
Recruiting
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/26/2025
Locations: Tucson Cystic Fibrosis Center, Tucson, Arizona
Conditions: Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Register for Updates
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842
Recruiting
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to cirrhosis. PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Arizona Liver Health, Tucson, Arizona
Conditions: Primary Biliary Cholangitis (PBC)
Register for Updates
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368
Recruiting
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/26/2025
Locations: Retina Associates SW, Tucson, Arizona
Conditions: Wet Age-related Macular Degeneration
Register for Updates
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450
Recruiting
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Research Site, Tucson, Arizona
Conditions: Viral Lung Infection and Acute Respiratory Failure
Register for Updates
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602
Recruiting
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Banner University Medical Center - Tucson, Tucson, Arizona +1 locations
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
A Study to Investigate Weight Management with LY3549492 Compared with Placebo in Adult Participants with Obesity or Overweight
NCT06683508
Recruiting
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/25/2025
Locations: The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson, Arizona
Conditions: Obesity, Overweight
Register for Updates
POLARx Post Approval Study (POLARx PAS)
NCT06170606
Recruiting
To collect clinical data on safety, effectiveness and procedural success of Boston Scientific's Cardiac Cryoablation System (includes all BSC commercially available POLARx/POLARx Fit catheters) when used to perform pulmonary vein isolation (PVI) in the ablation treatment of de novo Atrial Fibrillation (AF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Pima Heart & Vascular Clinical Research, Tucson, Arizona
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
NCT04726241
Recruiting
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
03/25/2025
Locations: Banner University Medical Center - Tucson, Tucson, Arizona
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
Register for Updates
Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension
NCT06526858
Recruiting
HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant hypertension on three(3) or more antihypertensive medications
Gender:
ALL
Ages:
Between 22 years and 80 years
Trial Updated:
03/25/2025
Locations: University of Arizona Department of Urology, Tucson, Arizona
Conditions: Resistant Hypertension
Register for Updates
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
NCT06453213
Recruiting
Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagno... Read More
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
03/25/2025
Locations: Center For Neurosciences, Tucson, Arizona
Conditions: Focal Onset Seizure
Register for Updates
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/25/2025
Locations: Research Site, Tucson, Arizona
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
NCT06856577
Recruiting
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to an active comparator. The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured at an aver... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/25/2025
Locations: Adverum Clinical Site 159, Tucson, Arizona
Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Register for Updates